Lipocine (NASDAQ:LPCN – Get Free Report) was downgraded by investment analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued to investors on Friday.
Lipocine Stock Up 2.2 %
NASDAQ LPCN opened at $3.67 on Friday. The stock has a market capitalization of $19.63 million, a P/E ratio of -2.15 and a beta of 1.12. Lipocine has a 52-week low of $2.31 and a 52-week high of $11.79. The firm has a 50-day moving average price of $5.67 and a 200 day moving average price of $5.50.
Lipocine (NASDAQ:LPCN – Get Free Report) last issued its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter. The business had revenue of $0.09 million for the quarter. On average, equities research analysts expect that Lipocine will post -1 earnings per share for the current fiscal year.
Institutional Trading of Lipocine
About Lipocine
Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.
Further Reading
- Five stocks we like better than Lipocine
- What is a Bond Market Holiday? How to Invest and Trade
- Birkenstock’s Sudden Slide—Why It Might Be Your Next Big Win
- Compound Interest and Why It Matters When Investing
- Why Dell Can Continue Winning in AI and Beyond
- Dividend Capture Strategy: What You Need to Know
- Veeva’s Stock Jumps on Stellar Q2 Results—Don’t Miss Out
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.